Lead-Time Bias
Lead-time bias makes screening appear to extend survival simply because a disease is diagnosed earlier, even when the time of death is unchanged.
Don't Just Read it – Explore It
Lead-time bias makes screening appear to extend survival simply because a disease is diagnosed earlier, even when the time of death is unchanged.
Length-time bias explained: learn why screening more often detects slow-growing disease and can make outcomes look better than they are.
Surrogate endpoints explained: learn how biomarkers can stand in for clinical outcomes, speed research, and sometimes leave uncertainty about real benefit.
Overdiagnosis explained: learn how screening can find real abnormalities that would never cause harm, and why benefits and risks must be weighed.
Overtreatment explained: understand when medical care may add burden without meaningful benefit and how shared decisions can reduce unnecessary harm.
Pharmacovigilance explained: see how safety signals, adverse-event reports, studies, and regulatory action monitor medicines after approval.
Antimicrobial stewardship promotes careful antibiotic and antifungal use to improve outcomes, limit side effects, and slow drug resistance.
Preventive care uses screenings, vaccines, counseling, and routine checkups to reduce disease risk and detect health problems early.
Medical coding explained: learn how diagnoses, procedures, supplies, and services become standardized codes used in records and claims.
Generic medicines explained: learn how generics compare with brand-name drugs in active ingredient, performance, appearance, and cost.
Biosimilars explained: learn how these biologic medicines compare with reference products and how interchangeability differs from generic substitution.
Number needed to treat explained: learn how NNT summarizes absolute benefit, why timeframe matters, and what the number leaves out.